SODIUM PERTECHNETATE TC 99M
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SODIUM PERTECHNETATE TC 99M (SODIUM PERTECHNETATE TC 99M).
Sodium pertechnetate Tc-99m is a radiopharmaceutical that emits gamma rays (140 keV). The pertechnetate anion (TcO4−) is taken up by the thyroid gland via the sodium-iodide symporter (NIS) and also distributes in salivary glands, gastric mucosa, and choroid plexus. It acts as a diagnostic imaging agent by localizing in tissues via active transport or diffusion, allowing external detection with gamma cameras.
| Metabolism | Sodium pertechnetate Tc-99m is not metabolized. It is excreted unchanged primarily via the kidneys (glomerular filtration) with a biological half-life of about 6 hours. A small fraction may be secreted into the gastrointestinal tract via saliva and gastric juices. |
| Excretion | Renal: approximately 30-50% of the injected dose is excreted in urine within 24 hours. The remainder is eliminated via the hepatobiliary system into feces. |
| Half-life | Terminal elimination half-life: approximately 6 hours. Clinical context: Allows for imaging up to several hours post-injection; clearance is delayed in renal impairment. |
| Protein binding | Minimal; less than 5% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: approximately 0.3 L/kg. Indicates distribution primarily into extracellular fluid and some intracellular compartments in thyroid and stomach tissues. |
| Bioavailability | Intravenous: 100%. Not administered via other routes clinically. |
| Onset of Action | Intravenous: Immediate, as pertechnetate ion is rapidly distributed to target organs (thyroid, salivary glands, stomach) within minutes. |
| Duration of Action | Effective imaging window: 30 minutes to 2 hours post-injection for thyroid scans; up to 4 hours for other applications due to ongoing uptake and clearance. |
370-1110 MBq (10-30 mCi) intravenously as a single dose for brain imaging; 370-740 MBq (10-20 mCi) intravenously for thyroid imaging; 185-370 MBq (5-10 mCi) intravenously for salivary gland imaging.
| Dosage form | SOLUTION |
| Renal impairment | No significant renal excretion; dose adjustment not required for impaired renal function. |
| Liver impairment | No dose adjustment necessary for hepatic impairment. |
| Pediatric use | Weight-based: 0.05-0.21 mCi/kg (1.85-7.77 MBq/kg) intravenously, minimum 0.5 mCi (18.5 MBq). For brain imaging: 0.14 mCi/kg (5.18 MBq/kg). |
| Geriatric use | No specific dose adjustment; use lowest effective dose to minimize radiation exposure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SODIUM PERTECHNETATE TC 99M (SODIUM PERTECHNETATE TC 99M).
| Breastfeeding | Sodium pertechnetate Tc 99m is excreted into breast milk. M/P ratio is approximately 1.0. The American College of Radiology recommends interrupting breastfeeding for 24 hours after administration. Pump and discard milk during this period. |
| Teratogenic Risk | First trimester: Sodium pertechnetate Tc 99m crosses the placenta; fetal thyroid can accumulate pertechnetate after approximately 12 weeks gestation. No evidence of teratogenicity from diagnostic doses. Second and third trimesters: Fetal thyroid radiation dose is significant; use with caution only if benefit justifies risk. Avoid administration near term to reduce neonatal thyroid exposure. |
■ FDA Black Box Warning
None
| Serious Effects |
["Absolute: None known.","Relative: Pregnancy (unless benefit outweighs risk); lactation (consider temporary cessation); patients with known hypersensitivity to pertechnetate (extremely rare)."]
| Precautions | ["Radiopharmaceutical: Use only by authorized personnel; minimize radiation exposure to patients and staff.","Pregnancy: Consider benefits vs. radiation risk; alternative imaging may be preferred.","Lactation: Interrupt breastfeeding for at least 4-12 hours after administration to reduce infant radiation dose.","Hydration: Encourage fluid intake to promote urinary excretion and reduce bladder radiation dose.","Allergic reactions: Rare; have emergency resuscitation equipment available.","False positives: Prior administration of other Tc-99m compounds or perchlorate may interfere with uptake."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for diagnostic use. Assess hydration status to promote urinary excretion. In pregnancy, confirm gestational age and ensure radiation dose is minimized per ALARA principle. |
| Fertility Effects | No known effects on fertility at diagnostic doses. High-dose exposure (not applicable to diagnostic Tc-99m) may cause gonadal radiation effects. |